Leveraging Northway Biotech’s 20+ years of CDMO expertise, Kaida BioPharma is advancing KAD101, a targeted therapy for ...

Roivant has its own TYK2/JAK1 inhibitor in development in the form of brepocitinib, which the biopharma licensed from Pfizer ...

"We are proud to partner with Kaida BioPharma on the development of KAD101,” said Prof. Vladas Algirdas Bumelis, CEO and ...

Genentech signs $105M upfront deal with Orionis Biosciences to develop molecular glue cancer drugs, with potential milestones ...

Pfizer on Tuesday announced a cancer drug licensing deal with Chinese biotech 3SBio that includes a $1.25 billion upfront ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

Hyderabad-based Bharat Biotech International Ltd. has claimed that its oral cholera vaccine (OCV) under development, Hillchol ...

FBT ETF launched 19 years ago and has delivered exceptional returns compared to the broader Health Care sector. Read why FBT ...

The acquisition marks a turning point for the company after months of financial uncertainty and data breach concerns.

Bharat Biotech’s oral cholera vaccine, Hillchol, aims to ease a critical global shortfall, with the world currently lacking ...

Bharat Biotech's Hillchol OCV, effective against cholera serotypes, aims to provide affordable, accessible vaccines for ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...